TABLE OF CONTENTS

BY DOMAIN

12-LEAD ECG 11
BASELINE/DAY 1 11
SCREENING 11
UNSCHEDULED 11
WEEK 1 11
WEEK 12 11
ADVERSE EVENT SUMMARY 12
ADVERSE EVENTS 12
ADVERSE EVENT 13
ADVERSE EVENTS 13
COMPLETE PHYSICAL EXAMINATION 15
BASELINE/DAY 1 15
EARLY TERMINATION 15
POST-TREATMENT FOLLOW-UP WEEK 4 15
POST-TREATMENT FOLLOW-UP WEEK 24 15
SCREENING 15
UNSCHEDULED 15
WEEK 12 15
WEEK 24 15
CONCOMITANT MEDICATION SUMMARY 16
CONCOMITANT MEDICATION 16
CONCOMITANT MEDICATION 17
CONCOMITANT MEDICATION 17
DEATH REPORT 18
DEATH 18
DEMOGRAPHICS 19
SCREENING 19
DOSE ADMINISTRATION (DAY 1) 20
BASELINE/DAY 1 20
DOSE ADMINISTRATION (SERIAL PK) 21
WEEK 2 21
DOSE ADMINISTRATION (SINGLE PK) 22
EARLY TERMINATION 22

UNSCHEDULED 22
WEEK 1 22
WEEK 2 22
WEEK 4 22
WEEK 6 22
WEEK 8 22
WEEK 10 22
WEEK 12 22
WEEK 16 22
WEEK 20 22
WEEK 24 22
DOSE ADMINISTRATION (VIRAL DYNAMIC SUBSTUDY) 23
DAY 2 23
DAY 3 23
DAY 4 23
DAY 5 23
DAY 10 23
GENERAL COMMENTS 24
INCLUSION/EXCLUSION CRITERIA 28
SCREENING 28
INTERFERON CLASSIFICATION 32
SCREENING 32
INTERFERON INELIGIBILITY REASONS 33
SCREENING 33
INTERFERON INTOLERANT REASONS 34
SCREENING 34
INVESTIGATOR'S SIGNATURE 35
LIVER FIBROSIS ASSESSMENT 36
SCREENING 36
MEDICAL HISTORY 38
SCREENING 38
MISSED DOSE AND OVERDOSE LOG 39
PK PLASMA (VIRAL DYNAMIC SUBSTUDY DAY 1) 40
BASELINE/DAY 1 40
PREGNANCY REPORT 41
PRIOR HCV TREATMENT HISTORY 42
SCREENING 42
RANDOMIZATION 44

BASELINE/DAY 1 44
REGISTRY SUBSTUDY 45
STUDY COMPLETION 45
SERIAL PK PLASMA 46
WEEK 2 46
SINGLE PK PLASMA 47
DAY 2 47
DAY 3 47
DAY 4 47
DAY 5 47
DAY 10 47
EARLY TERMINATION 47
UNSCHEDULED 47
WEEK 1 47
WEEK 2 47
WEEK 4 47
WEEK 6 47
WEEK 8 47
WEEK 10 47
WEEK 12 47
WEEK 16 47
WEEK 20 47
WEEK 24 47
STUDY COMPLETION 48
STUDY COMPLETION 48
STUDY DRUG ACCOUNTABILITY - GS-5885 49
STUDY DRUG ACCOUNTABLITY 49
STUDY DRUG ACCOUNTABILITY - GS-9451 50
STUDY DRUG ACCOUNTABLITY 50
STUDY DRUG ACCOUNTABILITY - RBV/PLACEBO 51
STUDY DRUG ACCOUNTABLITY 51
STUDY DRUG ACCOUNTABILITY - TEGOBUVIR/PLACEBO 52
STUDY DRUG ACCOUNTABLITY 52
STUDY DRUG ADMINISTRATION 53
STUDY DRUG ADMINISTRATION 53
STUDY DRUG COMPLETION 54
STUDY DRUG COMPLETION 54
SUBJECT FOLLOW-UP STATUS 55

POST-TREATMENT FOLLOW-UP WEEK 4 55
POST-TREATMENT FOLLOW-UP WEEK 8 55
POST-TREATMENT FOLLOW-UP WEEK 12 55
POST-TREATMENT FOLLOW-UP WEEK 16 55
POST-TREATMENT FOLLOW-UP WEEK 20 55
POST-TREATMENT FOLLOW-UP WEEK 24 55
SUBJECT NUMBER 56
URINE PREGNANCY TEST (BASELINE) 57
BASELINE/DAY 1 57
URINE PREGNANCY TEST 58
POST-TREATMENT FOLLOW-UP MONTH 6 58
POST-TREATMENT FOLLOW-UP WEEK 4 58
POST-TREATMENT FOLLOW-UP WEEK 8 58
POST-TREATMENT FOLLOW-UP WEEK 12 58
POST-TREATMENT FOLLOW-UP WEEK 16 58
POST-TREATMENT FOLLOW-UP WEEK 20 58
POST-TREATMENT FOLLOW-UP WEEK 24 58
UNSCHEDULED 58
WEEK 4 58
WEEK 8 58
WEEK 12 58
WEEK 16 58
WEEK 20 58
WEEK 24 58
VISIT DATE 59
BASELINE/DAY 1 59
DAY 2 59
DAY 3 59
DAY 4 59
DAY 5 59
DAY 10 59
EARLY TERMINATION 59
POST-TREATMENT FOLLOW-UP WEEK 4 59
POST-TREATMENT FOLLOW-UP WEEK 12 59
POST-TREATMENT FOLLOW-UP WEEK 24 59
SCREENING 59
UNSCHEDULED 59
WEEK 1 59

WEEK 2 59
WEEK 4 59
WEEK 6 59
WEEK 8 59
WEEK 10 59
WEEK 12 59
WEEK 16 59
WEEK 20 59
WEEK 24 59
VITAL SIGNS (SCREENING) 60
SCREENING 60
VITAL SIGNS WITH WEIGHT 61
BASELINE/DAY 1 61
EARLY TERMINATION 61
UNSCHEDULED 61
WEEK 12 61
WEEK 24 61
VITAL SIGNS 62
DAY 4 62
POST-TREATMENT FOLLOW-UP WEEK 4 62
UNSCHEDULED 62
WEEK 1 62
WEEK 2 62
WEEK 4 62
WEEK 6 62
WEEK 8 62
WEEK 10 62
WEEK 16 62
WEEK 20 62

BY VISIT

SCREENING 59
VISIT DATE 59
INCLUSION/EXCLUSION CRITERIA 28
DEMOGRAPHICS 19
VITAL SIGNS (SCREENING) 60
COMPLETE PHYSICAL EXAMINATION 15
MEDICAL HISTORY 38
LIVER FIBROSIS ASSESSMENT 36

12-LEAD ECG 11
INTERFERON CLASSIFICATION 32
INTERFERON INELIGIBILITY REASONS 33
INTERFERON INTOLERANT REASONS 34
PRIOR HCV TREATMENT HISTORY 42
BASELINE/DAY 1 59
VISIT DATE 59
RANDOMIZATION 44
VITAL SIGNS WITH WEIGHT 61
COMPLETE PHYSICAL EXAMINATION 15
URINE PREGNANCY TEST (BASELINE) 57
DOSE ADMINISTRATION (DAY 1) 20
PK PLASMA (VIRAL DYNAMIC SUBSTUDY DAY 1) 40
12-LEAD ECG 11
DAY 2 59
VISIT DATE 59
DOSE ADMINISTRATION (VIRAL DYNAMIC SUBSTUDY) 23
SINGLE PK PLASMA 47
DAY 3 59
VISIT DATE 59
DOSE ADMINISTRATION (VIRAL DYNAMIC SUBSTUDY) 23
SINGLE PK PLASMA 47
DAY 4 59
VISIT DATE 59
VITAL SIGNS 62
DOSE ADMINISTRATION (VIRAL DYNAMIC SUBSTUDY) 23
SINGLE PK PLASMA 47
DAY 5 59
VISIT DATE 59
DOSE ADMINISTRATION (VIRAL DYNAMIC SUBSTUDY) 23
SINGLE PK PLASMA 47
WEEK 1 59
VISIT DATE 59
VITAL SIGNS 62
DOSE ADMINISTRATION (SINGLE PK) 22
SINGLE PK PLASMA 47
12-LEAD ECG 11
DAY 10 59

VISIT DATE 59
DOSE ADMINISTRATION (VIRAL DYNAMIC SUBSTUDY) 23
SINGLE PK PLASMA 47
WEEK 2 59
VISIT DATE 59
VITAL SIGNS 62
DOSE ADMINISTRATION (SINGLE PK) 22
DOSE ADMINISTRATION (SERIAL PK) 21
SINGLE PK PLASMA 47
SERIAL PK PLASMA 46
WEEK 4 59
VISIT DATE 59
VITAL SIGNS 62
URINE PREGNANCY TEST 58
DOSE ADMINISTRATION (SINGLE PK) 22
SINGLE PK PLASMA 47
WEEK 6 59
VISIT DATE 59
VITAL SIGNS 62
DOSE ADMINISTRATION (SINGLE PK) 22
SINGLE PK PLASMA 47
WEEK 8 59
VISIT DATE 59
VITAL SIGNS 62
URINE PREGNANCY TEST 58
DOSE ADMINISTRATION (SINGLE PK) 22
SINGLE PK PLASMA 47
WEEK 10 59
VISIT DATE 59
VITAL SIGNS 62
DOSE ADMINISTRATION (SINGLE PK) 22
SINGLE PK PLASMA 47
WEEK 12 59
VISIT DATE 59
VITAL SIGNS WITH WEIGHT 61
COMPLETE PHYSICAL EXAMINATION 15
URINE PREGNANCY TEST 58
DOSE ADMINISTRATION (SINGLE PK) 22

SINGLE PK PLASMA 47
12-LEAD ECG 11
WEEK 16 59
VISIT DATE 59
VITAL SIGNS 62
URINE PREGNANCY TEST 58
DOSE ADMINISTRATION (SINGLE PK) 22
SINGLE PK PLASMA 47
WEEK 20 59
VISIT DATE 59
VITAL SIGNS 62
URINE PREGNANCY TEST 58
DOSE ADMINISTRATION (SINGLE PK) 22
SINGLE PK PLASMA 47
WEEK 24 59
VISIT DATE 59
VITAL SIGNS WITH WEIGHT 61
COMPLETE PHYSICAL EXAMINATION 15
URINE PREGNANCY TEST 58
DOSE ADMINISTRATION (SINGLE PK) 22
SINGLE PK PLASMA 47
EARLY TERMINATION 59
VISIT DATE 59
VITAL SIGNS WITH WEIGHT 61
COMPLETE PHYSICAL EXAMINATION 15
DOSE ADMINISTRATION (SINGLE PK) 22
SINGLE PK PLASMA 47
STUDY DRUG COMPLETION 54
STUDY DRUG COMPLETION 54
POST-TREATMENT FOLLOW-UP WEEK 4 59
VISIT DATE 59
VITAL SIGNS 62
COMPLETE PHYSICAL EXAMINATION 15
URINE PREGNANCY TEST 58
SUBJECT FOLLOW-UP STATUS 55
POST-TREATMENT FOLLOW-UP WEEK 8 58
URINE PREGNANCY TEST 58
SUBJECT FOLLOW-UP STATUS 55

POST-TREATMENT FOLLOW-UP WEEK 12 59
VISIT DATE 59
URINE PREGNANCY TEST 58
SUBJECT FOLLOW-UP STATUS 55
POST-TREATMENT FOLLOW-UP WEEK 16 58
URINE PREGNANCY TEST 58
SUBJECT FOLLOW-UP STATUS 55
POST-TREATMENT FOLLOW-UP WEEK 20 58
URINE PREGNANCY TEST 58
SUBJECT FOLLOW-UP STATUS 55
POST-TREATMENT FOLLOW-UP WEEK 24 59
VISIT DATE 59
COMPLETE PHYSICAL EXAMINATION 15
URINE PREGNANCY TEST 58
SUBJECT FOLLOW-UP STATUS 55
POST-TREATMENT FOLLOW-UP MONTH 6 58
URINE PREGNANCY TEST 58
ADVERSE EVENTS 12
ADVERSE EVENT SUMMARY 12
ADVERSE EVENT 13
CONCOMITANT MEDICATION 16
CONCOMITANT MEDICATION SUMMARY 16
CONCOMITANT MEDICATION 17
STUDY DRUG ADMINISTRATION 53
STUDY DRUG ADMINISTRATION 53
STUDY DRUG ACCOUNTABLITY 49
STUDY DRUG ACCOUNTABILITY - GS-5885 49
STUDY DRUG ACCOUNTABILITY - GS-9451 50
STUDY DRUG ACCOUNTABILITY - TEGOBUVIR/PLACEBO 52
STUDY DRUG ACCOUNTABILITY - RBV/PLACEBO 51
DEATH 18
DEATH REPORT 18
UNSCHEDULED 59
VISIT DATE 59
VITAL SIGNS 62
VITAL SIGNS WITH WEIGHT 61
COMPLETE PHYSICAL EXAMINATION 15
URINE PREGNANCY TEST 58

DOSE ADMINISTRATION (SINGLE PK) 22
SINGLE PK PLASMA 47
12-LEAD ECG 11
STUDY COMPLETION 48
STUDY COMPLETION 48
REGISTRY SUBSTUDY 45
MISSED DOSE AND OVERDOSE LOG 39
PREGNANCY REPORT 41
GENERAL COMMENTS 24
INVESTIGATOR'S SIGNATURE 35
SUBJECT NUMBER 56

Project Name: GS-US-248-0132
Form: 12-Lead ECG *[ECG12]*
Generated On: Jul-31-2013 11:45:40

Was an ECG performed?	☐ Yes ☐ No
If No, please comment why ECG was not done:	
Date of ECG:	/ /
Time of ECG:	:
HR Rate (bpm):	
PR Interval (msec):	
QRS Interval (msec):	
QT Interval (msec):	
QTcF Interval (msec) (Calculated)	
Overall Assessment of ECG:	☐ Normal ☐ Abnormal
If Abnormal, please describe the abnormality:	
Significance of Abnormality:	☐ Not Clinically Significant ☐ Clinically Significant

Did the subject experience any Adverse Events during the course of the study?	☐ Yes ☐ No

Project Name: GS-US-248-0132
Form: Adverse Event *[AE]*
Generated On: Jul-31-2013 11:45:40

Adverse Event: (List diagnosis or each symptom separately)	
AE serious: (If the Adverse Event is Serious, please click the [?] help text to open the SAE Report Form in another window. Print and fill in all the information for the first three pages on the SAE form and fax to the appropriate CRO contact)	☐ Yes ☐ No
Start Date: (DD-MMM-YYYY)	/ /
End Date: (DD-MMM-YYYY)	/ /
Please check if Ongoing:	☐
Related to any of the Study Drugs: (All study drugs are to be considered in assessment of relationship to study drugs: GS-5885, GS-9451, Tegobuvir/Placebo , RBV/Placebo)	☐ Yes ☐ No
Related to Study Procedures:	☐ Yes ☐ No
Study Drug Action Taken - GS-5885:	☐ No change ☐ Interrupted ☐ Discontinued ☐ Dose Reduced
Study Drug Action Taken - GS-9451:	☐ No change ☐ Interrupted ☐ Discontinued ☐ Dose Reduced
Study Drug Action Taken - Tegobuvir/Placebo:	☐ No change ☐ Interrupted ☐ Discontinued ☐ Dose Reduced

Study Drug Action Taken - RBV/Placebo:	☐ No change ☐ Interrupted ☐ Discontinued ☐ Dose Reduced
Severity:	☐ Mild ☐ Moderate ☐ Severe ☐ Life-Threatening
Other Action Taken: (Check all that apply) None:	☐
Medication Required:	☐
Other Treatment Required:	☐
Hospitalized/Prolonged Hospitalization:	☐
Hidden field for AE_AESER_ALERT	

Note: To add additional adverse events, please complete an additional form, by clicking on 'Add a new log line'.

If Adverse Event is Serious, please refer to the regulatory binder for an SAE Report form. Complete an SAE Report and E-mail or fax the SAE Report within 24 hours of the Reporter's knowledge of the event. Contact information for faxing and e-mailing this form is found in the study protocol in section 8.5.1.

A Serious Adverse Event is any adverse experience that results in any of the following outcomes:
(1) Death,
(2) Is life-threatening (at immediate risk of death at time of the event),
(3) Requires subject hospitalization or prolonged hospitalization,
(4) Persistent or significant disability/incapacity,
(5) Congenital abnormality/birth defect or
(6) Any other important Medical Event based on clinician's judgment or may require medical or surgical intervention to prevent one of the other serious criteria.
Refer to protocol for protocol-specific SAE definitions.

Select a response for each body system. If a body system is not examined, select "Not Done."

Body System	☐ Head, Neck & Thyroid ☐ Eyes, Ears, Nose, Throat, Mouth & Tongue ☐ Chest (Excluding breasts) ☐ Respiratory ☐ Cardiovascular ☐ Lymph Nodes ☐ Abdomen ☐ Skin, Nails & Hair ☐ Musculoskeletal ☐ Neurological ☐ Retinal Exam Results ☐ Other
If Body System is Other, please specify:	
Result:	☐ Abnormal ☐ Normal ☐ Not Done
If "Abnormal", please describe abnormal physical findings:	

If additional Body Systems are needed then click on 'Add New Log Line' at the bottom of the form.

Did the subject take any Medications from time of informed consent signing through study completion?	☐ Yes ☐ No

Drug Name:	
Indication: (Use Medical Terminology)	
Route:	☐ Inhalation ☐ Intradermal ☐ Intralesional ☐ Intramuscular ☐ Intranasal ☐ Intravenous ☐ Intraocular ☐ Intraperitoneal ☐ Oral ☐ Rectal ☐ Subcutaneous ☐ Sublingual ☐ Topical ☐ Vaginal ☐ Other
If "Other", please specify:	
Start Date: (DD-MMM-YYYY)	/ /
Stop Date: (DD-MMM-YYYY)	/ /
Please check if Ongoing:	☐

Note: To add additional concomitant medications, please complete an additional form, by clicking on 'Add a new log line'.

Project Name: GS-US-248-0132
Form: Death Report *[DEATH]*
Generated On: Jul-31-2013 11:45:40

In addition to this eCRF, please refer to the regulatory binder for an SAE Report form. Complete an SAE Report and E-mail or fax the SAE Report within 24 hours of the Reporter's knowledge of the event. Please also send a copy of the discharge/death summary and autopsy report, if available.

Contact information for faxing and e-mailing these forms is found in the study protocol in section 8.5.1(Click the [?] help text to open the SAE Report Form in another window. Please fill in all appropriate information on the first three pages before faxing the forms to the appropriate CRO contact.)

Please update the Adverse Event eCRF, as needed.

Date of Death: (DD-MMM-YYYY)	/ /
Immediate Cause of Death:	

Date of Birth: (DD-MMM-YYYY)	/ /
Age:	
Sex:	☐ Male ☐ Female
Ethnicity:	☐ Hispanic or Latino ☐ Not Hispanic or Latino ☐ Not Permitted
Race:	☐ American Indian or Alaska Native ☐ Asian ☐ Black or African Heritage ☐ Native Hawaiian or Pacific Islander ☐ White ☐ Not Permitted ☐ Other
If "Other", please specify:	
Year of Birth (yyyy)	/ /

Name of Actual Treatment:	☐ GS-5885 ☐ GS-9451 ☐ Tegobuvir/Placebo ☐ RBV/Placebo
Date of First Dose: (DD-MMM-YYYY)	/ /
Time of First Dose: (00:00-23:59)	:
Dose:	
Dose Units:	☐ mg ☐ ug ☐ tablets ☐ capsules
Dose Taken With Food	☐ Yes ☐ No

Project Name: GS-US-248-0132
Form: Dose Administration (Serial PK) *[PKEX2]*
Generated On: Jul-31-2013 11:45:40

Dose Timepoint:	☐ Pre-PK Day Dose ☐ PK Day AM Dose ☐ PK Day PM Dose ☐ Post-PK Day AM Dose
Name of Actual Treatment:	☐ GS-5885 ☐ GS-9451 ☐ Tegobuvir/Placebo ☐ RBV/Placebo
Date of Dose: (DD-MMM-YYYY)	/ /
Time of Dose: (00:00-23:59)	:
Dose:	
Dose Units:	☐ mg ☐ ug ☐ tablets ☐ capsules
Dose Taken With Food:	☐ Yes ☐ No

Project Name: GS-US-248-0132
Form: Dose Administration (Single PK) *[PKEX1]*
Generated On: Jul-31-2013 11:45:40

Check 'Not Applicable' box if Subject is participating in Serial PK Substudy at this visit:	☐
Name of Actual Treatment:	☐ GS-5885 ☐ GS-9451 ☐ Tegobuvir/Placebo ☐ RBV/Placebo
Date of Dose prior to Sample Draw: (DD-MMM-YYYY)	/ /
Time of Dose prior to Sample Draw: (00:00-23:59)	:
Dose:	
Dose Units:	☐ mg ☐ ug ☐ tablets ☐ capsules
Dose Taken With Food	☐ Yes ☐ No

Project Name: GS-US-248-0132
Form: Dose Administration (Viral Dynamic Substudy) *[PKEX3]*
Generated On: Jul-31-2013 11:45:40

Name of Actual Treatment:	☐ GS-5885 ☐ GS-9451 ☐ Tegobuvir/Placebo ☐ RBV/Placebo
Date of Dose prior to Sample Draw: (DD-MMM-YYYY)	/ /
Time of Dose prior to Sample Draw: (00:00-23:59)	:
Dose:	
Dose Units:	☐ mg ☐ ug ☐ tablets ☐ capsules
Dose Taken With Food:	☐ Yes ☐ No

Visit:

- ☐ Screening
- ☐ Initial Treatment Visits
- ☐ Baseline/Day 1
- ☐ Week 1
- ☐ Week 2
- ☐ Week 4
- ☐ Week 6
- ☐ Week 8
- ☐ Week 10
- ☐ Week 12
- ☐ Week 16
- ☐ Week 20
- ☐ Week 24
- ☐ Early Termination (Initial Treatment)
- ☐ Study Drug Completion (Initial Treatment)
- ☐ PK and/or Viral Dynamic Substudies
- ☐ Day 1
- ☐ Day 2
- ☐ Day 3
- ☐ Day 4
- ☐ Day 5
- ☐ Day 10
- ☐ PK Week 2
- ☐ Post-Treatment Follow-Up Visits
- ☐ Post-Treatment Follow-Up Week 4
- ☐ Post-Treatment Follow-Up Week 8
- ☐ Post-Treatment Follow-Up Week 12
- ☐ Post-Treatment Follow-Up Week 16
- ☐ Post-Treatment Follow-Up Week 20

- [ ] Post-Treatment Follow-Up Week 24
- [ ] Post-Treatment Follow-Up Month 6
- [ ] Adverse Events
- [ ] Concomitant Medication
- [ ] Study Drug Administration
- [ ] Study Drug Accountability
- [ ] Pregnancy Report
- [ ] Death
- [ ] General Comments
- [ ] Unscheduled
- [ ] Study Completion
- [ ] Missed Dose Overdose Log

Form:

- [ ] Adverse Event
- [ ] Adverse Event Summary
- [ ] Complete Physical Examination
- [ ] Concomitant Medication
- [ ] Concomitant Medication Summary
- [ ] Death Report
- [ ] Demographics
- [ ] Dose Administration (Day 1)
- [ ] Dose Administration (Single PK)
- [ ] Dose Administration (Serial PK)
- [ ] Dose Administration (Viral Dynamic Substudy)
- [ ] General Comments
- [ ] Inclusion/Exclusion Criteria
- [ ] Investigator's Signature
- [ ] Liver Fibrosis Assessment
- [ ] Medical History
- [ ] Pregnancy Report
- [ ] Randomization
- [ ] Single PK Plasma
- [ ] Serial PK Plasma
- [ ] PK Plasma (Viral Dynamic Substudy Day 1)
- [ ] Stop Treatment
- [ ] Study Completion
- [ ] Study Drug Accountability - GS-5885
- [ ] Study Drug Accountability - GS-9451
- [ ] Study Drug Accountability - Tegobuvir//Placebo
- [ ] Study Drug Accountability - RBV
- [ ] Study Drug Administration - Initial Treatment
- [ ] Study Drug Completion (Initial Treatment)

	☐ Subject Follow-Up Status ☐ Urine Pregnancy Test ☐ Urine Pregnancy Test (Baseline) ☐ Visit Date ☐ 12-Lead ECG ☐ Missed Dose and Overdose Log – Initial Treatment ☐ Prior HCV Treatment History ☐ Interferon Classification ☐ Interferon Ineligibility Reasons ☐ Interferon Intolerant Reasons ☐ Vital Signs ☐ Vital Signs (Screening) ☐ Vital Signs with Weight
General Comments:	
General Comments (Continued)	

Note: To add additional comments, please complete an additional form, by clicking on 'Add a new log line'.

Date informed Consent Signed: (DD-MMM-YYYY)	/ /
Under which protocol version was the subject enrolled?	☐ Original ☐ Amendment 1
Was subject a Screen Failure?	☐ Yes ☐ No
Did the subject meet all eligibility criteria?	☐ Yes ☐ No

If "No", Please complete the following (Please tick all Inclusion criteria not met or Exclusion criteria met):

Inclusion/Exclusion criteria:

- [ ] Inclusion 1
- [ ] Inclusion 2
- [ ] Inclusion 3
- [ ] Inclusion 4
- [ ] Inclusion 5
- [ ] Inclusion 6
- [ ] Inclusion 7
- [ ] Inclusion 8
- [ ] Inclusion 9
- [ ] Inclusion 10
- [ ] Inclusion 11
- [ ] Inclusion 12
- [ ] Inclusion 13
- [ ] Inclusion 14
- [ ] Inclusion 15
- [ ] Inclusion 16
- [ ] Inclusion 17
- [ ] Exclusion 1
- [ ] Exclusion 2
- [ ] Exclusion 3
- [ ] Exclusion 4
- [ ] Exclusion 5
- [ ] Exclusion 6
- [ ] Exclusion 7
- [ ] Exclusion 8
- [ ] Exclusion 9
- [ ] Exclusion 10
- [ ] Exclusion 11
- [ ] Exclusion 12

	☐ Exclusion 13 ☐ Exclusion 14 ☐ Exclusion 15 ☐ Exclusion 16 ☐ Exclusion 17 ☐ Exclusion 18 ☐ Exclusion 19 ☐ Exclusion 20 ☐ Exclusion 21 ☐ Exclusion 22 ☐ Exclusion 23 ☐ Exclusion 24 ☐ Exclusion 25 ☐ Exclusion 26 ☐ Exclusion 27 ☐ Exclusion 28 ☐ Exclusion 29
Inclusion criteria not met/Exclusion criteria met?	☐
If subject that did not meet inclusion/exclusion criteria was enrolled, please provide an explanation.	
For subjects who are screen failures but meet eligibility criteria - ONLY: Provide the most significant reason why the subject was not randomized in the IWRS.	☐ Adverse Event ☐ Investigator Decision ☐ Subject Withdrew Consent ☐ Lost to Follow-Up ☐ Outside of Visit Window ☐ Study Enrollment Closed ☐ Other

If "Other", specify:

Please indicate if subject is interferon ineligible or interferon intolerant	☐ Interferon ineligible ☐ Interferon intolerant

Please choose the primary Interferon Ineligibility Reason as per Inclusion Criteria #6.

If additional secondary reasons are present, please click on the 'Add a new log line' link at the bottom of the table below.

Primary/Secondary Reasons	☐ Primary Reason ☐ Secondary Reason(s)
Interferon Ineligibility Reasons as per Inclusion Criteria #6	☐ Autoimmune Disorder ☐ Significant Psychiatric Disease ☐ Seizure Disorder ☐ Thyroid Dysfunction ☐ Retinal Disease ☐ Poorly Controlled Diabetes ☐ Other (as approved by the Medical Monitor)
Interferon Ineligibility Reasons Specify	
Date of Diagnosis:(DD-MMM-YYYY)	/ /

Please choose the primary Interferon Intolerant Reason as per Inclusion Criteria #6.

If additional secondary reasons are present, please click on the 'Add a new log line' link at the bottom of the table below.

Primary/Secondary Reasons	☐ Primary Reason ☐ Secondary Reason(s)
Interferon Intolerant Reasons as per Inclusion Criteria #6	☐ Significant Local or Systemic Adverse Reaction ☐ Psychiatric Disease ☐ Significant Cognitive Impairment ☐ Neuropathy ☐ Disabling Flu-Like Symptoms ☐ Gastrointestinal Toxicity ☐ Thrombocytopenia ☐ Neutropenia ☐ Retinal Disease ☐ Autoimmune Disorder ☐ Other (as approved by the Medical Monitor)
Interferon Intolerant Reason Specify	
Date of Onset	/ /

Project Name: GS-US-248-0132

Form: Investigator's Signature *[INVSIG]*

Generated On: Jul-31-2013 11:45:41

By entering my Medidata password, I affirm that I have reviewed and evaluated the case reportforms and verify that they accurately reflect the information in the source documents for thissubject. I understand source documentation can include (but is not limited to) medical records,laboratory results, x-rays, electronic communications, etc.	

LIVER BIOPSY

Check if Biopsy not done:	☐
Date of Liver Biopsy: (DD-MMM-YYYY)	/ /
Fibrosis Staging Method:	☐ Metavir ☐ Ishak ☐ Knodell ☐ Batts-Ludwig ☐ Scheuer
Fibrosis Staging Result:	☐ F0 ☐ F0-F1 ☐ F1 ☐ F1-F2 ☐ F2 ☐ F2-F3 ☐ F3 ☐ F3-F4 ☐ F4 ☐ F5 ☐ F6
Cirrhosis:	☐ Yes ☐ No

NON-INVASIVE ALTERNATIVE TO LIVER BIOPSY

Check if not done:	☐
Date of Procedure: (DD-MMM-YYYY)	/ /

Method:	☐ FibroTest ☐ FibroScan ☐ Acoustic Radiation Force Impulse Imaging ☐ Other
If Method is Other, please specify:	
Result:	
Cirrhosis	☐ Yes ☐ No

Please record date of diagnosis for Hepatitis C on row 1 and indicate if ongoing by checking the 'Ongoing' box.

In addition, click on the 'Add a new Log line' link below and add any relevant medical history.

Condition:	
Start Date: (DD-MMM-YYYY)	/ /
Stop Date: (DD-MMM-YYYY)	/ /
Check if Condition is Ongoing:	☐

Note: To add additional Medical History entries, please complete an additional form, by clicking on 'Add a new log line'.

Project Name: GS-US-248-0132
Form: Missed Dose and Overdose Log *[EXMSOV]*
Generated On: Jul-31-2013 11:45:41

Only enter a record for days on which the dairy indicates a missed dose or overdose of a study drug. Enter all dosing information for that day.

If a subject mistook an evening dose for the QD drugs GS-9451 or GS-5885 and this was indicated in the dairy, please enter them in the last two columns. If an evening dose of GS-9451 or GS-5885 were not taken, please leave the column blank.

Date (dd-mmm-yyyy)	/ /
Morning Dosing: Please record number of tablets taken: **Ribavirin**	
Morning Dosing: Please record number of capsules taken: **Tegobuvir**	
Morning Dosing: Please record number of tablets taken: **GS-9451**	
Morning Dosing: Please record number of tablets taken: **GS-5885**	
Evening Dosing: Please record number of tablets taken: **Ribavirin**	
Evening Dosing: Please record number of capsules taken: **Tegobuvir**	
Evening Dosing: Please record number of tablets taken: **GS-9451**	
Evening Dosing: Please record number of tablets taken: **GS-5885**	

If and overdose of study drug has been reported, please click on the [?] help text to open the Oversdose Form in another window. Fax or email the completed form to the appropriate CRO contact.

Will a serial PK profile be collected for this subject?	☐ Yes ☐ No

IF YES, COMPLETE THE REMAINDER OF THIS FORM

Date of PK Collection: (DD-MMM-YYYY)	/ /
Dose Time Point:	☐ Collection Time 4.0 Hours Post-dose ☐ Collection Time 6.0 Hours Post-dose ☐ Collection Time 8.0 Hours Post-dose
Time of PK Collection: (00:00-23:59)	:
Not Collected	☐
Please specify why this timepoint was not collected:	

Project Name: GS-US-248-0132
Form: Pregnancy Report *[PREGREP]*
Generated On: Jul-31-2013 11:45:41

If a pregnancy occurs, please complete as much information as possible on this form.

In addition to this eCRF, refer to the regulatory binder and complete the 'Pregnancy Report' and email or fax the report within 24 hours of the Reporter's knowledge of the event. When the outcome of the pregnancy is known, complete the 'Pregnancy Outcome Report'.(Click the [?] help text to open the Pregnancy Report Form in another window. Please fill in all information before faxing the forms to the appropriate CRO contact.)

Contact information for faxing and e-mailing these forms to the CRO during the conduct of the study is found in the study protocol in section 8.5.1. Additional reporting details may be found in protocol section 8.7.

Please also report the pregnancy to the Ribavirin Pregnancy Registry at ribavirinpregnancyregistry.com

Last Menstrual Period: (DD-MMM-YYYY)	/ /
Pregnancy Confirmed: (DD-MMM-YYYY)	/ /
Estimated Date of Delivery: (DD-MMM-YYYY) **(Click the [?] help text to open the Pregnancy Outcome Report Form in another window. Please fill in all information on the first 3 pages before faxing the forms to the appropriate CRO contact.)**	/ /

HCV Treatment:	☐ Interferon-alfa ☐ Pegylated Interferon-alfa ☐ Other Interferon (specify) ☐ Ribavirin ☐ Other HCV treatment (specify)
HCV treatment Specify	
Starting Dose:	
Dose Unit:	☐ IU ☐ Ug ☐ ug/kg ☐ Mg ☐ Other
Dose Unit Specify	
Frequency	☐ Once a Week ☐ Three Times a Day ☐ Once a Day ☐ Twice a Week ☐ Other
Frequecy Specify	
Start Date: (DD-MMM-YYYY)	/ /
Stop Date: (DD-MMM-YYYY)	/ /
Start Year (yyyy)	/ /

Stop Year (yyyy)	/ /

Note: All baseline tests and procedures, including ECGs, must be completed prior to randomization and dosing/dispensing of GS-5885, GS-9451, Tegobuvir/Placebo or RBV/Placebo.

Was the Subject Randomized?	☐ Yes ☐ No
4-Digit Subject Number as assigned by IWR system	
Will the subject participate in the PK Substudy?	☐ Yes ☐ No
Date of PK Substudy Consent (DD-MMM-YYYY)	/ /
Will the subject participate in the Viral Dynamic Substudy?	☐ Yes ☐ No
Date of Viral Dynamic Substudy Consent: (DD-MMM-YYYY)	/ /
Will the subject participate in Pharmacogenomic Testing?	☐ Yes ☐ No
Date of Pharmacogenomic Testing Consent: (DD-MMM-YYYY)	/ /
RANDNUM+Z_SUBID	

Which Registry study is the subject eligible to enroll in?	☐ None ☐ SVR Registry (248-0122) ☐ Sequence Registry (248-0123) ☐ NA, Site Not Participating
Will the subject enroll in the registry study?	☐ Yes ☐ No
If No, state the primary reason why the subject will not enroll?	☐ Subject is not interested in participating ☐ Subject will receive other HCV treatment ☐ Lost to follow-up ☐ Other
Other, specify	

Will a serial PK profile be collected for this subject?	☐ Yes ☐ No

IF YES, COMPLETE THE REMAINDER OF THIS FORM

Date of PK Collection: (DD-MMM-YYYY)	/ /
PK Time Point:	☐ Collection Time Pre-dose ☐ Collection Time 1.0 Hour Post-dose ☐ Collection Time 2.0 Hours Post-dose ☐ Collection Time 3.0 Hours Post-dose ☐ Collection Time 4.0 Hours Post-dose ☐ Collection Time 6.0 Hours Post-dose ☐ Collection Time 8.0 Hours Post-dose ☐ Collection Time 10.0 Hours Post-dose ☐ Collection Time 12.0 Hours Post-dose ☐ Collection Time 24.0 Post-dose
Time of PK Collection: (00:00-23:59)	:
Not Collected	☐
Please specify why this timepoint was not collected:	
Collection Time 24.0 Hours Post-Dose: Not Collected	☐
Collection Time 24.0 Hours Post-Dose: Date of PK Collection: (DD-MMM-YYYY)	/ /
Collection Time 24.0 Hours Post-Dose: Time of PK Collection: (00:00-23:59)	:
Collection Time 24.0 Hours Post-Dose: Please specify why this timepoint was not collected:	

Project Name: GS-US-248-0132
Form: Single PK Plasma *[PK]*
Generated On: Jul-31-2013 11:45:41

Was Single PK Plasma Sample collected?	☐ Yes ☐ No
Date of PK Collection: (DD-MMM-YYYY)	/ /
Time of PK Collection: (00:00-23:59)	:

Did the subject complete the protocol-planned duration of the study?	☐ Yes ☐ No
If "No", please specify reason for study discontinuation.	☐ Adverse Event ☐ Death ☐ Pregnancy ☐ Efficacy Failure ☐ Protocol Violation ☐ Subject Withdrew Consent ☐ Lost to Follow-Up ☐ Investigator Decision ☐ Study Discontinued by Sponsor

Visit Dispensed:	☐ Baseline ☐ Week 4 ☐ Week 8 ☐ Week 12 ☐ Week 16 ☐ Week 20 ☐ Unscheduled
Drug Name:	☐ GS-5885 ☐ GS-9451 ☐ RBV/Placebo ☐ Tegobuvir/Placebo ☐ GS-5885 Rescue Therapy ☐ GS-9451 Rescue Therapy ☐ RBV Rescue Therapy ☐ Tegobuvir/Placebo Rescue Therapy ☐ PEG Rescue Therapy
Date Dispensed:	/ /
5-Digit Bottle Number:	
Number of Tablets Dispensed:	
Date Returned:	/ /
Number of Tablets Returned:	
Study Drug Not Returned:	☐

Visit Dispensed:	☐ Baseline ☐ Week 4 ☐ Week 8 ☐ Week 12 ☐ Week 16 ☐ Week 20 ☐ Unscheduled
Drug Name:	☐ GS-5885 ☐ GS-9451 ☐ RBV/Placebo ☐ Tegobuvir/Placebo ☐ GS-5885 Rescue Therapy ☐ GS-9451 Rescue Therapy ☐ RBV Rescue Therapy ☐ Tegobuvir/Placebo Rescue Therapy ☐ PEG Rescue Therapy
Date Dispensed:	/ /
5-Digit Bottle Number:	
Number of Tablets Dispensed:	
Date Returned:	/ /
Number of Tablets Returned:	
Study Drug Not Returned:	☐

Project Name: GS-US-248-0132
Form: Study Drug Accountability - RBV/Placebo *[DA4]*
Generated On: Jul-31-2013 11:45:41

Visit Dispensed:	☐ Baseline ☐ Week 4 ☐ Week 8 ☐ Week 12 ☐ Week 16 ☐ Week 20 ☐ Unscheduled
Drug Name:	☐ GS-5885 ☐ GS-9451 ☐ RBV/Placebo ☐ Tegobuvir/Placebo ☐ GS-5885 Rescue Therapy ☐ GS-9451 Rescue Therapy ☐ RBV Rescue Therapy ☐ Tegobuvir/Placebo Rescue Therapy ☐ PEG Rescue Therapy
Date Dispensed:	/ /
5-Digit Bottle Number:	
Number of Tablets Dispensed:	
Date Returned:	/ /
Number of Tablets Returned:	
Study Drug Not Returned:	☐

Visit Dispensed:	☐ Baseline ☐ Week 4 ☐ Week 8 ☐ Week 12 ☐ Week 16 ☐ Week 20 ☐ Unscheduled
Drug Name:	☐ GS-5885 ☐ GS-9451 ☐ RBV/Placebo ☐ Tegobuvir/Placebo ☐ GS-5885 Rescue Therapy ☐ GS-9451 Rescue Therapy ☐ RBV Rescue Therapy ☐ Tegobuvir/Placebo Rescue Therapy ☐ PEG Rescue Therapy
Date Dispensed:	/ /
5-Digit Bottle Number:	
Number of Capsules Dispensed:	
Date Returned:	/ /
Number of Capsules Returned:	
Study Drug Not Returned:	☐

Project Name: GS-US-248-0132
Form: Study Drug Administration *[EX]*
Generated On: Jul-31-2013 11:45:41

Drug Name:	☐ GS-5885 ☐ GS-9451 ☐ Tegobuvir/Placebo ☐ RBV/Placebo
Dose:	
Dose Units / Frequency:	☐ capsules/day ☐ tablets/day ☐ Other
If “Other”, please specify:	
Start Date: (DD-MMM-YYYY)	/ /
Stop Date: (DD-MMM-YYYY)	/ /
Ongoing:	☐
Check box if study drug was permanently discontinued:	☐

Did subject complete study drug treatment through Week 24?	☐ Yes ☐ No
If “No”, please specify reason for study drug discontinuation:	☐ Adverse Event ☐ Death ☐ Pregnancy ☐ Efficacy Failure ☐ Protocol Violation ☐ Subject Withdrew Consent ☐ Lost to Follow-Up ☐ Investigator Decision ☐ Randomized but Subject Never Dosed with Study Drug ☐ Study Discontinued by Sponsor

Project Name: GS-US-248-0132
Form: Subject Follow-Up Status *[DS]*
Generated On: Jul-31-2013 11:45:41

Provide the subject status:

If subject has discontinued, please complete the Study Completion form. For female subjects of childbearing potential, please also continue to complete the follow-up Urine Pregnancy Tests until Month 6

Project Name: GS-US-248-0132
Form: Subject Number *[SUBID]*
Generated On: Jul-31-2013 11:45:41

Screening Number (XXX):	
Subject Initials (XXX):	
SCRNID + SUBJINIT	

Project Name: GS-US-248-0132
Form: Urine Pregnancy Test (Baseline) *[PREGTEST1]*
Generated On: Jul-31-2013 11:45:41

Is female subject of childbearing potential?	☐ Yes ☐ No
Date Test Performed: (DD-MMM-YYYY)	/ /
Test Result:	☐ Negative ☐ Positive ☐ Not Done

Note: A positive urine pregnancy test must be immediately confirmed with a serum pregnancy test, and the subject must not be enrolled.

Project Name: GS-US-248-0132
Form: Urine Pregnancy Test *[PREGTEST]*
Generated On: Jul-31-2013 11:45:41

Is female subject of childbearing potential?	☐ Yes ☐ No
Date Test Performed: (DD-MMM-YYYY)	/ /
Test Result:	☐ Negative ☐ Positive ☐ Not Done

Note: A positive urine pregnancy test must be immediately confirmed with a serum pregnancy test.

Was Post-Treatment Follow-Up Week 4 visit performed?	☐ Yes ☐ No
Visit Date: (DD-MMM-YYYY)	/ /
Was visit performed on the same day as Week 1	☐ Yes ☐ No
Reason for Unscheduled Visit: (Check all that apply) Evaluation of AE and/or Concomitant Medications:	☐
Vital Signs:	☐
Physical Exam:	☐
ECG:	☐
PK:	☐
Lab Evaluations:	☐
Study Drug Adjustment or Dispensation:	☐
Other:	☐
Other, Specify:	

Project Name: GS-US-248-0132
Form: Vital Signs (Screening) *[VS1]*
Generated On: Jul-31-2013 11:45:42

Weight:	kg/ lb
Height:	cm/ in
Blood Pressure Systolic: (mmHg)	
Blood Pressure Diastolic: (mmHg)	
Pulse (beats/minute):	
Respiration: (breaths/minute)	
Temperature:	Celsius/ Fahrenheit

Project Name: GS-US-248-0132
Form: Vital Signs with Weight *[VS2]*
Generated On: Jul-31-2013 11:45:42

Weight:	kg/ lb
Blood Pressure Systolic: (mmHg)	
Blood Pressure Diastolic: (mmHg)	
Pulse (beats/minute):	
Respiration: (breaths/minute)	
Temperature:	Celsius/ Fahrenheit

Project Name: GS-US-248-0132
Form: Vital Signs *[VS]*
Generated On: Jul-31-2013 11:45:42

Blood Pressure Systolic: (mmHg)	
Blood Pressure Diastolic: (mmHg)	
Pulse (beats/minute):	
Respiration: (breaths/minute)	
Temperature:	Celsius/ Fahrenheit